KING OF PRUSSIA, PA — SEED Therapeutics, Inc. has been named a finalist for the 2025 Prix Galien USA “Best Start-Up” Award, a distinction often referred to as the “Nobel Prize” of biopharmaceutical and medical technology innovation. The honor recognizes the company’s leadership in developing molecular glue degraders to address diseases with significant unmet medical needs.
The nomination follows the FDA’s recent clearance of an investigational new drug application for SEED’s lead candidate, ST-01156, a RBM39 degrader. Built on its proprietary RITE3™ platform, SEED designs targeted protein degradation therapies that leverage the body’s ubiquitin-proteasome system to selectively eliminate disease-causing proteins.
Founded by a team that includes Nobel Laureate Avram Hershko and leading structural biology experts, SEED counts Eli Lilly and Eisai among its strategic partners. Winners will be announced October 30, 2025, at the American Museum of Natural History in New York City.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.